Health & Biotech
Health: ResApp popping bottles in the ice as cough app finally gets approval; shares fly
Creso extends its global reach with new deal in South Africa
Weed Week: Can cannabis help alleviate gridiron injuries?
MGC Pharma raises $4.8m ahead of UK listing
Virtus shares weaken as costs rise amid profit fall
Creso receives first commercial CBD export from Colombia ahead of PharmaCielo acquisition
Health: Investment from a DNA sequencer sends Race Oncology flying
Dr Boreham’s Crucible: Opthea needs some big licks of dough, but it has set itself up for success
Health: Pharmaxis tumbles way into the red as fortunes fluctuate on handballed drug
What the small fries can learn from health and biotech mega caps
Weed Week: Start of an Asian Spring?
Health: Human cell proteins + cannabis = fountain of youth?
Aussie momentum building for MGC Pharma amid milestones
Health: This mouthguard maker is now kicking off medicinal cannabis trials
Micro-encapsulation matters and this $5.5 million infant formula deal proves it
How Australia is missing a multi-billion-dollar hemp opportunity
Dr Boreham’s Crucible: It’s glory or bust as Shareroot ramps up its social standing
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.
